-

$undefined

N/A

(N/A)

Apellis Pharmaceuticals NASDAQ:APLS Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. Leaders in targeted C3 therapies, the company aims to develop transformative therapies for a broad range of debilitating diseases that are driven by excessive activation of the complement cascade, including those within hematology, ophthalmology, nephrology, and neurology.

Location: 100 Fifth Avenue, Massachusetts, 02451, United States | Website: apellis.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing

Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

3.49B

Cash

403.7M

Avg Qtr Burn

-51.28M

Short % of Float

20.53%

Insider Ownership

14.02%

Institutional Own.

Qtr Updated

09/30/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
SYFOVRE™ (Intravitreal pegcetacoplan) Details Geographic atrophy, Age-related macular degeneration	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Empaveli (systemic pegcetacoplan) (APL-2) Details Paroxysmal nocturnal hemoglobinuria	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Systemic pegcetacoplan (APL-2) Details Immune complex membranoproliferative glomerulonephritis, C3 Glomerulopathy	sNDA Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Systemic pegcetacoplan (APL-2) Details Hematopoietic stem cell transplantation thrombotic microangiopathies	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Systemic pegcetacoplan (APL-2) Details Immune complex membranoproliferative glomerulonephritis, C3 Glomerulopathy	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
APL-3007 (small interfering RNA silencing C3) Details Autoimmune disease, Inflammatory disease	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Systemic pegcetacoplan (APL-2) Details Amyotrophic lateral sclerosis	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Systemic pegcetacoplan (APL-2) Details Cold agglutinin disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Intravenous APL-9 Details ARDS (Acute respiratory distress syndrome), TMA (Thrombotic microangiopathies)	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.